To determine the incidence and risk factors in the development of ovarian, fallopian tube, and peritoneal cancers in Japanese women carrying Breast Cancer Susceptibility Gene (BRCA)1/2 variants.
Women carrying BRCA1/2 variants (those with either BRCA1 or BRCA2 variants, or those carrying both variants) and women carrying a variant of uncertain significance (VUS).
Women who have received sufficient genetic counseling at any medical institution, prior to enrollment to the study.
Women who provide consent should be 20 years of age or older.
Women who provide written consent.
Women without ovarian or fallopian tube cancer at the time of informed consent.
Women previously diagnosed with ovarian, fallopian tube, or peritoneal cancer, and not excluding those with a personal history of breast cancer development.
Other individuals considered inappropriate for involvement in this study by the investigator.
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Lead sponsor
Okayama University
Collaborator
Japanese Gynecologic Oncology Group
Collaborator